Latest Industry Projects

EMD Serono to Invest $12 Million to Expand Biopharmaceutical R&D Facility in Billerica, Massachusetts

EMD Serono to Invest $12 Million to Expand Biopharmaceutical R&D Facility in Billerica, Massachusetts

Introduction:

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in North America, today announced a $12 million investment for the expansion of its R&D facility in Billerica, Massachusetts.

Features:

The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with a focus on oncology, immuno-oncology and immunology. The purpose of this expansion is to advance innovation and knowledge-sharing across our R&D teams, with the goal of accelerating the discovery and development of new therapies for patients in need,” said Luciano Rossetti, MD, Head of Global R&D for Merck KGaA, Darmstadt, Germany.

The new two-story, 30,000 square foot building will be an extension of the existing Sagamore Building and will feature amenities including open plan work areas, a central auditorium, and numerous meeting spaces including bleacher seating for spontaneous collaboration and interaction. In addition to seeking LEED certification to complement the Sagamore Building’s Platinum LEED status, EMD Serono will also apply for the WELL Institute certification.

Construction on the expansion is scheduled to begin in May 2016 with a planned completion date of June 2017.

Specifications:

Name  EMD Serono
Location  Billerica, Massachusetts
Type  Expansion Of R&D Facility
Estimated Cost  $12 Million

 

Source : emdserono.com

Other Projects